Phase 2 Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01939899
Recruitment Status : Completed
First Posted : September 11, 2013
Last Update Posted : March 30, 2017
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : June 1, 2016
  Actual Study Completion Date : March 23, 2017
  Certification/Extension First Submitted : November 29, 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 March 20, 2018
April 18, 2018